Services

Health technology assessment

Advisory board management

Advisory boards allow you to gain independent critical feedback from world-leading clinicians and experts in health economics and outcomes research (HEOR). We draw on our extensive network of experts to recruit insightful and well-balanced advisory boards. We facilitate their discussions to ensure convergence into productive deliverables to inform your strategy.

Value and reimbursement strategies

Identifying value requires a deep understanding of HEOR, which is why we combine extensive technical skills with a creative problem-solving approach to craft a powerful narrative about the value of your product. Strategic insight requires a comprehensive understanding of stakeholder objectives, which is why we elicit and synthesise expertise from across the full range of HEOR stakeholders, allowing us to follow a thorough, strategic approach.

Reimbursement submissions (rapid delivery)

A high-quality reimbursement submission is key to securing market access. Our deep understanding of how HTA bodies make decisions helps us prepare successful submissions that transform a complex evidence base into a rigorous cost-effectiveness model and a compelling narrative.

Other services include:
Rare diseases
Gaining reimbursement for a drug targeting a rare disease
Author
Date
Neurology & mental health
Evaluating the cost-effectiveness of a medical device
Author
Date
Respiratory
Modelling survival after the clinical trials have ended
Author
Date
Policy and methods
Developing a framework for analysing the impact of patient-centred outcomes for achieving reimbursement in the UK
Author
Date
Cardiometabolic health
Evaluating the cost-effectiveness of a diagnostic device
Author
Date
Oncology
Overcoming limited evidence to gain reimbursement for a blockbuster oncology drug
Author
Date
Dermatology
Overcoming the short-term bias in clinical evidence to compare long-term efficacy of psoriasis treatments
Author
Date
Dermatology
Validating comparisons of disease treatments in the absence of head-to-head trials
Author
Date

Stay in touch

Subscribe to Symmetron and stay up to date with recent news and announcements.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
This is a testimonial. This is a testimonial. This is a testimonial. This is a testimonial. This is a testimonial.
This is a testimonial. This is a testimonial. This is a testimonial. This is a testimonial. This is a testimonial.
“The team went above and beyond our expectations for our project. We were grateful that Symmetron was able to meet our deadlines, and to deliver a very large volume of work”
“One of the most efficient partnerships I’ve had with an external group.”
“Symmetron has expertise in all areas, including project management, SLRs, NMAs, economic modelling and a good relationship with the medical writer.”
“Our expectations were met, and the project was handled at the highest level."
Gaining reimbursement for a drug targeting a rare disease
Gaining reimbursement for a drug targeting a rare disease
Evaluating the cost-effectiveness of a medical device
Evaluating the cost-effectiveness of a medical device
Modelling survival after the clinical trials have ended
Modelling survival after the clinical trials have ended
Developing a framework for analysing the impact of patient-centred outcomes for achieving reimbursement in the UK
Developing a framework for analysing the impact of patient-centred outcomes for achieving reimbursement in the UK
Evaluating the cost-effectiveness of a diagnostic device
Evaluating the cost-effectiveness of a diagnostic device
Overcoming limited evidence to gain reimbursement for a blockbuster oncology drug
Overcoming limited evidence to gain reimbursement for a blockbuster oncology drug
Overcoming the short-term bias in clinical evidence to compare long-term efficacy of psoriasis treatments
Overcoming the short-term bias in clinical evidence to compare long-term efficacy of psoriasis treatments
Validating comparisons of disease treatments in the absence of head-to-head trials
Validating comparisons of disease treatments in the absence of head-to-head trials